Capture Gelatrix Manufacturing Rights via Convertible Note Bridge
- Organization
- NSF SBIR Phase I funding structure (research capital without commercial infrastructure)
- Sector
- Orthopedic device strategic acquirers (Stryker, Zimmer, DePuy)
- Location
- Location unspecified
Source Reference
Executive Context
NSF awarded $305K SBIR Phase I funding to CYTROGEN for Gelatrix, a light-curable bone adhesive, creating a research-funded entity with technical validation capital but zero commercial infrastructure, manufacturing partnerships, or market access pathways.
Catalyst / Timing
CYTROGEN has $305K SBIR funding for technical feasibility but zero commercial infrastructure, manufacturing partnerships, or market access. The SBIR program requires a commercialization plan for Phase II but provides no resources to build it, creating a valley of death between research validation and commercial execution.
Projected Yield
$150K convertible note → potential $2-4M acquisition premium at Phase II exit (10-20x return on manufacturing rights position)
Structural Friction
• Vulnerability: CYTROGEN has $305K SBIR funding for technical feasibility but zero commercial infrastructure, manufacturing partnerships, or market access. The SBIR program requires a commercialization plan for Phase II but provides no resources to build it, creating a valley of death between research validation and commercial execution. • Capital yield: $150K convertible note → potential $2-4M acquisition premium at Phase II exit (10-20x return on manufacturing rights position) • Resource capture: First refusal position on all manufacturing partnerships for Gelatrix • Sovereignty yield: Exclusive manufacturing rights control over novel bone adhesive technology • Required vectors: Vector: Corporate Finance & Deal Structuring, Vector: FDA Regulatory Intelligence, Vector: Medical Device Manufacturing
Required Capabilities
Vector: Corporate Finance & Deal Structuring
Primary executor: Phase 1: IP & Development Status Intelligence: File FOIA request with NSF for CYTROGEN's Phase I proposal (excluding pro
Vector: FDA Regulatory Intelligence
Supporting vector for: Capture Gelatrix Manufacturing Rights via Convertible Note Bridge
Vector: Medical Device Manufacturing
Supporting vector for: Capture Gelatrix Manufacturing Rights via Convertible Note Bridge
Execution Protocol
Execution Protocol Locked
A one-time payment of $1799 unlocks the exact wedge, required assets, and step-by-step execution parameters yours forever, no subscription.
This report is synthesized intelligence, not verified instruction. Always confirm against the primary source before acting. Review the full legal disclaimer before proceeding.